MapLight Therapeutics MPLT

Christopher A. Kroeger, M.D., age 58, is our co-founder and has served as our Chief Executive Officer, President, and as a member of our Board of Directors since 2018. Dr. Kroeger previously served as Chief Executive Officer and on the board of directors of OvaScience, Inc., a female fertility company, from 2017 until its merger with Millendo Therapeutics, Inc. in 2018. Prior to joining OvaScience, Dr. Kroeger served as Chief Executive Officer and on the board of directors of Cardioxyl Pharmaceuticals, a biotechnology company focused on cardiovascular disease, from 2008 until its sale to Bristol Myers Squibb in 2015 (and he remained an employee of Bristol Myers Squibb through March 2016). Dr. Kroeger has also held positions at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies, beginning in 2003 and as a partner beginning in 2007. Dr. Kroeger earned his B.A. from Harvard University, his M.D. from the Stanford University School of Medicine and his M.B.A. from Harvard Business School. He did his residency in general surgery at the Brigham and Women's Hospital, an affiliate of Harvard Medical School.

Erin Pennock Foff, M.D., Ph.D., has served as our Chief Medical Officer since April 2021. Dr. Foff previously served in various roles at Acadia Pharmaceuticals Inc., a biopharmaceutical company focused on central nervous system disorders and rare diseases, from 2017 to April 2021, most recently as Executive Director of Clinical Development, where she led the company's programs in dementia/neurodegenerative disorders. Prior to joining Acadia Pharmaceuticals, Dr. Foff held an academic physician-scientist position at the University of Virginia from 2006 to 2018 as a cognitive neurologist with a subspecialty interest in early-onset dementing illnesses and ran a translational laboratory program investigating diseases of RNA toxicity and neurodegeneration. Dr. Foff earned her Ph.D. in molecular and human genetics from the Baylor College of Medicine and her M.D. from Jefferson Medical College. She completed her residency in neurology at the University of Virginia and holds a certification from the American Board of Psychiatry and Neurology.

Maria Walker, age 61, has served as a member of our Board of Directors since February 2024. Ms. Walker served as Founding Partner and Chief Financial Officer of Patient Square Capital, LP, a health care investment firm, from August 2020 to January 2024, and as a member of the board of directors and chair of the audit committee for ForgeRock, Inc., an identity and access management software company, from November 2019 to August 2023, when it was acquired by Thoma Bravo. Ms. Walker has served as a board member of Five9, Inc., a software company, since June 2024 and as audit committee chair since May 2025. Ms. Walker has also served as a board member and audit committee chair for Global Support and Development, Inc., a humanitarian non-profit,non-governmental organization, since June 2023 and in March 2024, she was appointed to serve as the Chairman. Ms. Walker served as Chief Financial Officer of Montes Archimedes Acquisition Corp, a special purpose acquisition company, from October 2020 until September 2021, when it merged with Roivant Sciences. Ms. Walker co-founded and served as Chief Executive Officer of Recuerdo Therapeutics, Inc., a biotechnology company focused on the postponement of Alzheimer's disease, from 2018 to February 2020. From 2008 to 2018, Ms. Walker held various leadership roles at KPMG U.S., a public accounting firm, including as Audit Partner, Senior Director of KPMG's Venture Capital Practice and a Global Lead Partner of Private Equity, and she led the San Francisco Bay Area Asset Management Practice. Ms. Walker holds a B.A. in Economics from the University of California, San Diego.

Timothy Garnett, M.B.B.S., age 64, has served as a member of our Board of Directors since July 2023. Dr. Garnett previously served in various roles at Eli Lilly and Company beginning in 1998, most recently as Chief Medical Officer from 2008 to April 2021. Dr. Garnett has served on the boards of directors of Cardiol Therapeutics, Inc., a life sciences company centered on developing treatments for heart disease, since June 2025, and Ophirex, Inc., a global health public benefit corporation, since June 2021. Dr. Garnett previously served on the board of directors of Carmot Therapeutics, Inc., a biotechnology company focused on metabolic diseases, from March 2022 to January 2024, when it was acquired by the Roche Group. He has served as an advisor to Biolojic Design, Ltd., a biotechnology company focused on autoimmune diseases and immuno-oncology, since November 2021, and Ukko Inc., a biotechnology company focused on allergies, since January 2022, as well as a member of the Advisory Panel of Cambridge Innovation Capital since June 2021. Dr. Garnett received a Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.) from St. George's London, and he is a Fellow of the Faculty of Pharmaceutical Medicine (F.F.P.M.) and a Fellow of the Royal College of Obstetricians and Gynaecologists (F.R.C.O.G.).

Dr. Nanna Liebach Luneborg, PhD, age 50, has served as a member of our Board of Directors since July 2025. Since September 2021, Dr. Luneborg has served as General Partner at Forbion, an investment firm focused on biotechnology. Dr. Luneborg previously served in various roles of increasing responsibility at Novo Holdings' Novo Ventures from 2012 to July 2021, most recently as Partner from 2018 to July 2021, where she focused on late-stage biopharma investments across Europe. Dr. Luneborg previously served on the board of directors of Lava Therapeutics N.V. from September 2020 to June 2022 and currently serves on the boards of directors of BioInvent International AB and several private companies. Dr. Luneborg has a Ph.D. in Neuroscience from University College London, an M.B.A. from the University of Cambridge and a B.A. in Physiology and Psychology from the University of Oxford.

George Pavlov, age 65, has served as a member of our Board of Directors since February 2019 and as Chair of the Board since May 2024. Since 2015, Mr. Pavlov has served as Chief Executive Officer of a private single-family office located in Silicon Valley, where he oversees a broad range of activities, including philanthropy. Previously, Mr. Pavlov served in various roles in the venture capital industry, most recently as General Partner of Tallwood Venture Capital, a venture capital firm, from 2000 to 2015, and he has served on the boards of directors for multiple private and public companies and nonprofit organizations. Mr. Pavlov earned a B.S. in accounting from Boston College.

The Board has nominated Martin Babler as Class I director nominee at the Company's Annual Meeting of Stockholders which will be held on June 23, 2026.

The Board has nominated Troy Cox as Class I director nominee at the Company's Annual Meeting of Stockholders which will be held on June 23, 2026.

effective June 18, 2026, Company appointed Jonathan Gillis, the Company's Chief Administrative and Accounting Officer, as the Company's interim Chief Financial Officer and interim principal financial officer. Jonathan Gillis has served as our Chief Administrative and Accounting Officer since March 2024 and served as our Chief Financial Officer from February 2019 to March 2024. Mr. Gillis previously served in various roles at OvaScience, Inc. from 2013 until its merger with Millendo Therapeutics, Inc. in 2018, most recently as Senior Vice President of Finance. Mr. Gillis earned his B.S. and M.S. in accounting from Babson College.

James Lillie, Ph.D., has served as our Chief Scientific Officer since 2019. Dr. Lillie previously served as Chief Scientific Officer at OvaScience, Inc. from 2018 until its merger with Millendo Therapeutics, Inc. in 2018. Prior to joining OvaScience, Dr. Lillie served in various roles at Sanofi Genzyme, a biotechnology company, from 2004 to 2017, most recently as Vice President of In Vitro Biology. Dr. Lillie earned his B.A. in German literature from Wesleyan University and his Ph.D. in biochemistry and molecular biology from Harvard University.

Anatol Kreitzer, Ph.D., has served as our Chief Discovery Officer since 2020. Dr. Kreitzer held various positions at the University of California, San Francisco from 2007 to April 2022, most recently as a professor of physiology and neurology, where he led a laboratory focused on the basal ganglia. Dr. Kreitzer earned his B.A. in linguistics from the University of California, Berkeley and his Ph.D. in neurobiology from Harvard University, and he completed his postdoctoral work at Stanford University.

Kristopher L. Hanson has served as our General Counsel since April 2023. Prior to joining us, Mr. Hanson served in various roles at PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company focused on cardiovascular diseases, beginning in October 2019, most recently as Senior Vice President and General Counsel beginning in February 2022. Mr. Hanson previously served as Vice President for Legal and Compliance and Head of Human Resources at Nalpropion Pharmaceuticals, LLC, a biopharmaceutical company focused on the treatment of weight loss, from July 2018 to October 2019, and at its predecessor company, Orexigen Therapeutics, as Vice President and Assistant General Counsel, from 2016 to 2018. Mr. Hanson began his career in private practice as a corporate lawyer at Morrison & Foerster LLP and Brobeck, Phleger & Harrison LLP, after having completed a clerkship for U.S. District Court Judge John S. Rhoades. Mr. Hanson earned his B.A. in political science from Georgetown University and his J.D. from the University of California, Los Angeles School of Law.